ALXO News and Press, ALX Oncology Holdings Inc. From 06/14/21

--Interim report completed by ALX for a standard ongoing non-clinical safety study --Based on the safety study results, the FDA has lifted a previously set partial clinical hold and cap on patient enrollment in ASPEN-03 and ASPEN-04 --The first of two distinct randomized...

ALX Oncology (ALXO) inks clinical trial collaboration and supply agreement with Eli Lilly (LLY) to evaluate the combination of ALX148, a next generation CD47 blocker, and Cyramza (ramucirumab), Lilly’s anti-VEGFR2 antibody, for the treatment of patients with HER2-positive gastric cance...

BURLINGAME, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- ALX Oncology (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and ...

BURLINGAME, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and...

ALX Oncology (ALXO): Q1 GAAP EPS of -$0.35 beats by $0.09.Cash and cash equivalents as of March 31, 2021 were $429.9 million. ALX Oncology believes its cash and cash equivalents is sufficient to fund planned operations through 2024.Press release. For further details see: ALX Oncology EP...

BURLINGAME, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended M...

The first patient has been dosed in ALX Oncology Holdings ([[ALXO]] -4.0%) and collaborator Merck's ([[MRK]] +0.8%) Phase 2 ASPEN-03 study evaluating the combination of ALX148, a CD47 blocker, with Keytruda (pembrolizumab), an anti-PD-1 therapy, for the treatment of patients with advance...

- The first of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated BURLINGAME, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developi...

Gainers: Brooklyn ImmunoTherapeutics (BTX) +58%.Regional Health Properties (RHE) +49%.Motus GI Holdings (MOTS) +31%.Bel Fuse (BELFB) +29%.Image Sensing Systems (ISNS) +23%.Farmmi (FAMI) +20%.CryoLife (CRY) +18%.Naked Brand (NAKD) +17%.Laureate Education (LAUR) +14%.Insignia Sys...

Gainers: Brooklyn ImmunoTherapeutics (BTX) +38%, Motus GI MOTS +32%, CryoLife (CRY) +16%, Mesoblast MESO +14%, Arcutis Biotherapeutics (ARQT) +10%.Losers: Ardelyx (ARDX) -13%, Pacific Biosciences of California (PACB) -13%, ALX Oncolo...